Roche Mantra Is “Pipeline, Pipeline, Pipeline;” R&D Surge Continues In 2008
Executive Summary
Roche spending increases on pharmaceutical research and development will continue to outpace sales gains in 2008, company executives said during the firm's fourth quarter financial review Jan. 30
You may also be interested in...
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
Teva R&D Spending Target Raised To 7.5% Of Sales
Teva Pharmaceuticals will boost research and development spending this year toward a new goal of 7.5 percent of sales, company executives announced during the firm's fourth quarter earnings call Feb. 12